Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared With Best Supportive Care in Patients With COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome

Trial Profile

A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared With Best Supportive Care in Patients With COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ravulizumab (Primary)
  • Indications Acute lung injury; Adult respiratory distress syndrome; COVID 2019 infections; COVID-19 pneumonia
  • Focus Registrational; Therapeutic Use
  • Sponsors Alexion AstraZeneca Rare Disease

Most Recent Events

  • 26 Aug 2022 This trial has been discontinued in Italy, according to European Clinical Trials Database record.
  • 22 Jul 2022 This trial has been completed in Italy, according to European Clinical Trials Database record.
  • 16 Sep 2021 Status changed from active, no longer recruiting to discontinued (as study met futility bar at interim analysis)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top